← Latest briefing

Health

Medical experts warn of risks and thin evidence for anti-aging growth hormone peptides

Popular peptides like sermorelin and tesamorelin are heavily promoted for longevity, but large-scale clinical trials in healthy adults are lacking.

The short version

  • Growth hormone-stimulating peptides are being widely marketed by telehealth providers and longevity clinics as anti-aging and fitness-enhancing elixirs.
  • Medical experts warn that there are no large-scale randomized controlled trials demonstrating the safety or efficacy of these compounds for performance or longevity in healthy adults.
  • Artificially boosting growth hormone levels carries serious potential risks, including joint pain, heart disease, stroke, and colon cancer, while unregulated gray-market products may contain bacterial contaminants.

Key facts

  • Growth hormone peptides such as sermorelin, tesamorelin, CJC-1295, and ipamorelin are widely promoted by wellness figures, telehealth providers, and longevity clinics as anti-aging and fitness-enhancing agents.[Scientific American]
  • Sermorelin was FDA-approved in 1997 for pediatric growth hormone deficiency but was discontinued in 2008 for commercial reasons, while tesamorelin was approved in 2010 to treat HIV-associated lipodystrophy.[Scientific American]
  • Other popular peptide compounds, including CJC-1295, ipamorelin, GHRP-2, and GHRP-6, have never received approval from the FDA.[Scientific American]
  • Excess growth hormone can cause serious adverse effects, including joint pain, acromegaly, heart disease, and an increased risk of stroke and colon cancer.[Scientific American]
  • A non-peer-reviewed analysis found that 40 to 70 percent of tested gray-market peptide samples failed basic quality criteria, with roughly 15 percent of a subset containing bacterial endotoxin contamination.[Scientific American]

What remains uncertain

  • The exact physical effects of taking sermorelin and other growth hormone peptides remain unknown for healthy adults due to a lack of large-scale randomized controlled trials for performance, body composition, or longevity.[Scientific American]

Sources